Search

Aurinia Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

16.73 0.97

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

16.48

Massimo

16.8

Metriche Chiave

By Trading Economics

Entrata

3.1M

37M

Vendite

5.5M

83M

P/E

Media del settore

7.3

57.366

EPS

0.28

Margine di Profitto

44.958

Dipendenti

128

EBITDA

4.8M

55M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+8.63% upside

Dividendi

By Acuity

Utili prossimi

3 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

331M

2.2B

Apertura precedente

15.76

Chiusura precedente

16.73

Notizie sul Sentiment di mercato

By Acuity

21%

79%

58 / 340 Classifica in Healthcare

Aurinia Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 ago 2026, 19:36 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment, despite pulling back from earlier session highs. No specific news was identified.

24 ago 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of declines observed over the past three sessions. No specific news was identified.

21 ago 2026, 23:06 UTC

Aurinia Pharmaceuticals Inc. shares are higher in after-market hours, reflecting routine trading activity and maintaining a position above the 20-day moving average.

20 ago 2026, 21:46 UTC

Aurinia Pharmaceuticals Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

19 ago 2026, 23:02 UTC

News

Aurinia Pharmaceuticals settled patent litigation with Teva, securing exclusivity for voclosporin until December 2036. Shares rose in after-hours trading following the announcement.

18 ago 2026, 19:56 UTC

Aurinia Pharmaceuticals Inc is trading higher today, though no specific news has been identified. Rising Treasury yields may pose challenges for equities.

17 ago 2026, 20:02 UTC

Social Media

Aurinia Pharmaceuticals shares are lower amid broader market declines and rising crude oil prices, despite some social media chatter about potential buyout interest.

14 ago 2026, 19:26 UTC

Aurinia Pharmaceuticals shares are higher today, rebounding after earlier volatility amid broader market concerns over disappointing U.S. retail sales figures.

13 ago 2026, 19:56 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite ongoing sales growth of Lupkynis and a recent acquisition of Kezar Life Sciences.

11 ago 2026, 20:06 UTC

Aurinia Pharmaceuticals Inc shares are trading lower today, continuing a trend of three consecutive daily declines amid no specific news to explain the movement.

10 ago 2026, 20:06 UTC

News

Aurinia Pharmaceuticals shares decline following multiple downgrades from research firms, despite Royal Bank of Canada raising its price target to $16.00.

7 ago 2026, 19:16 UTC

News

Aurinia Pharmaceuticals shares are lower today, despite earlier gains. RBC Capital raised the price target to $16.00 from $15.00, maintaining a Sector Perform rating.

6 ago 2026, 20:02 UTC

Event
News

Aurinia Pharmaceuticals reported second-quarter EPS of $0.28, exceeding estimates. The stock is higher today amid strong financial results and reaffirmed revenue guidance for 2026.

4 ago 2026, 19:46 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment and a decline in crude oil prices, which may benefit consumer spending.

3 ago 2026, 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

1 ago 2026, 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

31 lug 2026, 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

30 lug 2026, 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

29 lug 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

28 lug 2026, 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

27 lug 2026, 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

24 lug 2026, 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

22 lug 2026, 19:46 UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

21 lug 2026, 19:16 UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

20 lug 2026, 20:01 UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Confronto tra pari

Modifica del prezzo

Aurinia Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

8.63% in crescita

Previsioni per 12 mesi

Media 18 USD  8.63%

Alto 21 USD

Basso 16 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Aurinia Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

58 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
help-icon Live chat